cyc 202 has been researched along with stilbenes in 3 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (stilbenes) | Trials (stilbenes) | Recent Studies (post-2010) (stilbenes) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 13,935 | 245 | 7,836 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kramer, MP; Maurer, M; Wesierska-Gadek, J | 1 |
| Komina, O; Wesierska-Gadek, J | 1 |
| Kramer, MP; Wesierska-Gadek, J | 1 |
3 other study(ies) available for cyc 202 and stilbenes
| Article | Year |
|---|---|
Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Antioxidants; Breast Neoplasms; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA; Female; Flow Cytometry; Humans; Purines; Resveratrol; Roscovitine; Stilbenes | 2008 |
Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells.
Topics: Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinases; Flow Cytometry; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Phosphorylation; Protein Kinase Inhibitors; Purines; Resveratrol; Roscovitine; Stilbenes | 2008 |
Monitoring of long-term effects of resveratrol on cell cycle progression of human HeLa cells after administration of a single dose.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinases; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; HeLa Cells; Humans; Protein Kinase Inhibitors; Purines; Resveratrol; Ribonucleotide Reductases; Roscovitine; Stilbenes; Time Factors | 2009 |